Key result
TACE plus sorafenib achieves long-term survival in HCC with right atrial tumor thrombus.
Why the study?
Hepatocellular carcinoma with tumor thrombus extending to the right atrium is rare and associated with an unfavorable prognosis.
Case Report (n=1)
Hepatocellular carcinoma (HCC) is considered to be the fourth most frequent cause of cancer-associated death globally. HCC might be associated, especially in advanced stages, with the formation of tumor thrombus (TT), which can be located in the portal vein, as well as in hepatic and/or inferior vena cava (IVC) veins. Nevertheless, the extension of TT to the right atrium (RA) is infrequent with an unfavorable prognosis. We present a rare case of a male patient with HCC and IVC TT extending to the RA. The atrial thrombus was the first manifestation of HCC diagnosed by cardiac ultrasound. So far, the patient has undergone 4 courses of transarterial chemoembolization in combination with systemic therapy with sorafenib, and under this therapeutic approach long-term survival has been achieved.
No takes yet. Share an insight, caveat, or question.
Mavroudis et al. (2020) conducted a case report in Hepatocellular carcinoma with tumor atrial thrombus (n=1). Transarterial chemoembolization and sorafenib was evaluated on Survival. Transarterial chemoembolization combined with sorafenib achieved long-term survival in a male patient with hepatocellular carcinoma and tumor thrombus extending to the right atrium.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: